Rhythm Pharmaceuticals enters the back half of August with an unusual split: the analyst community is uniformly raising targets after a strong earnings print, while short sellers have quietly rebuilt positions to their highest level in at least six weeks.
The Street reaction to the August 4 earnings beat has been unambiguous. JP Morgan initiated coverage on July 27 at Overweight with a $145 target, then raised it to $146 just five days after the print. RBC Capital was more aggressive, lifting its target from $141 to $155 — a 10% jump — while maintaining Outperform. Citigroup and Citizens also raised targets post-results. Every recent analyst move has been in one direction: higher. The consensus target now sits at $141.53, roughly 25% above the current price of $112.85, and forward EPS estimate momentum ranks in the 94th percentile of the universe — a signal that the analyst community sees the growth runway as intact.
The short interest picture has evolved since last week's note. Bears lifted their position from around 14.2% of the free float at the time of the August 4 earnings article to 14.5% now — a modest but steady rebuild that has added roughly 5% to shares short over the past month. The total short interest has climbed from roughly 8.2 million shares in early July to 9.7 million, making this the most crowded the short book has been in at least six weeks. Notably, the borrow market is not signalling any stress: cost to borrow remains low at 0.50%, and availability is extremely loose at roughly 1,350% — meaning lenders have close to 47 million shares available against 9.7 million already borrowed. There is no squeeze pressure of any kind in the lending pool.
Options positioning has normalised since the extreme call surge on earnings day. The put/call ratio now runs at 0.35, still well below its 20-day average of 0.45 and sitting 1.5 standard deviations below the mean. That is no longer the extreme four-standard-deviation reading from August 4, but it remains clearly call-heavy, consistent with investors holding onto upside exposure after the beat rather than rolling into protection. The 52-week high on the PCR is 1.00; the current level is closer to the annual low of 0.08 than to that defensive peak.
Institutional ownership tells a broadly constructive story. BlackRock added 132,000 shares as of July 31, State Street added 302,000 over the same window, and T. Rowe Price built a 283,000-share position in the quarter. Westfield Capital added 662,000 shares by end of June. The dominant holders — RA Capital at 9.7% and Baker Bros. at 8.1% — held flat, suggesting specialist biotech money is content to sit rather than add at current levels. Insider activity has been limited to routine awards and one small open-market sale by the Chief Scientific Officer in July, with no signal of directional conviction from management.
The recent earnings print produced a clean 7.7% next-day gain and a 9.8% five-day move — the stock's response to results has been positive. The next earnings event is not until November 3, leaving the coming weeks focused on clinical newsflow around IMCIVREE's pipeline indications and the Phase 3 oral MC4R program. With short interest elevated, call positioning dominant, and the Street unanimously pointing higher, the central question heading into that window is whether the clinical data calendar provides the catalyst to close the gap between the stock at $112.85 and the analyst consensus north of $140.
See the live data behind this article on ORTEX.
Open RYTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
